# IGC Pharma Reports $0.32 Million in Third-Quarter Revenue

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/52968
Published: 2026-11-10T09:42:20.000Z
Updated: 2026-11-10T09:42:20.000Z
Section: Business

> Net loss attributable to common stockholders widened to $2.046 million from $1.821 million, while basic and diluted loss per share was 2 cents.

IGC Pharma, Inc. reported third-quarter revenue of $0.32 million and a wider net loss attributable to common stockholders.

Third-quarter revenue was $0.32 million. Net loss attributable to common stockholders widened to $2.046 million from $1.821 million. Basic and diluted net loss per share was 2 cents.